期刊文献+

LRIG2基因全长及胞外段对胶质瘤细胞系U251细胞增殖和凋亡的影响 被引量:1

Effects of the full length and ectodomain of LRIG2 gene on proliferation and apoptosis of glioma cell line U251 cells
在线阅读 下载PDF
导出
摘要 目的探讨富含亮氨酸重复序列免疫球蛋白样蛋白2(LRIG2)基因全长及胞外段对脑胶质瘤细胞系U251细胞增殖和凋亡的影响。方法将LRIG2全长,LRIG2胞外段(LRIG2ecto)及空白质粒(对照)经慢病毒法分别转染胶质瘤细胞系U251细胞,筛选稳定细胞株,实时PCR及免疫印迹法检测mRNA及蛋白表达,细胞增殖检测试剂盒检测细胞增殖,流式细胞分析检测细胞周期及细胞凋亡。结果两转染组Flag标签蛋白表达成功;两转染组LRIG2全长及LRIG2ectomRNA表达较对照组明显升高(P<0.01);两转染组细胞增殖率均明显高于对照组(P<0.01);两转染组S期与G2/M期细胞数之和(即细胞增殖指数)均明显高于对照组(P<0.01),而细胞凋亡率均明显低于对照组(P<0.05)。结论 LRIG2基因全长及LRIG2ecto促进胶质瘤细胞增殖,并将细胞周期阻滞于G2/M期,抑制细胞凋亡。 Objective To explore the effects of the leucine-rich repeats and immunoglobulin-like domains-2 (LRIG2) gene full length and LRIG2 ectodomain (LRIG2_ecto) on proliferation and apoptosis of glioma cell line U251 cells. Methods The lentiviral vectors expressing the full length andLRIG2_ecto were transfected into glioblastoma cell line U251 cells respectively. The expression levels of LR1G2 and LRIG2_ecto mRNA and protein in the U251 cells were determined respectively by realtime PCR and western blotting. The U251 cells proliferation was determined by cell counting kit-8 (CCK-8). The U25l cells cycle distribution and apoptosis were detected by flow cytometry. Results The Flag proteins were successfully expressed in both the transfected groups. The mRNA expressions levels of LRIG2 andLRIG2_ecto, were significantly higher in the transfected U251 cells than those in the control ceils (P〈0.01). The proliferation rates were significantly higher in the transfected U251 cells than those in the control cells (P〈0.01). The proliferation indexes were significantly higher and the apoptotic rates were significantly lower in the transfected U251 ceils than those in the control cells (P〈0.01). ConclusiQn Both LRIG2 full length andLRIG2_ecto may promote the proliferation and inhibit the apoptosis of glioma cell line U251 cells.
出处 《中国临床神经外科杂志》 2013年第1期30-33,共4页 Chinese Journal of Clinical Neurosurgery
基金 国家自然科学基金资助项目(NO:81001116)
  • 相关文献

参考文献10

  • 1Holmlund C, Nilsson J, Guu D, et al. Characlerization andtissue-specific expression of human LK1G2 [J|. Gene, 2004,332: 35-43.
  • 2Holmlund C, Haapaaalo H, Yi W, et al. Cytoplasmic LHIG2expression is associated with poor oligodendroglioma patientsurvival[J].Neuropathology, 2009, 29(3): 242-247.
  • 3曾令成,欧一博,雷霆,郭东生.LRIG1在脑膜瘤中的表达及与其生物学行为的关系[J].中国临床神经外科杂志,2007,12(10):601-604. 被引量:7
  • 4杨洪宽,毛峰,万锋,张华楸,王宝峰,郭东生,雷霆.LRIG3基因对脑胶质瘤细胞系U87和U251的细胞周期、侵袭性和凋亡的影响[J].中国临床神经外科杂志,2011,16(4):220-223. 被引量:4
  • 5Ye F, Gao Q, Xu T, et al. Upregulation of LRIG1 suppressesmalignant glioma cell growth by attenuating EGFR activity[J]. J Neurooncol, 2009, 94(2): 183-194.
  • 6Goldoni S,Iozzo RA, Kay P, et al. A soluble ectodomain ofLRIG1 inhibits cancer cell growth by attenuating basal andligand-dependent EGFR*activity [J]. Oncogene, 2007, 26(3): 368-381.
  • 7Cai M, Han L,Chen R, et al. Inhibition of LRIG3 gene ex-pression via RNA interference modulates the proliferation,cell cycle, cell apoptosis, adhesion and invasion of gliobla-stoma cell (GL15) [J]. Cancer Lett, 2009, 278(1): 104-112.
  • 8Castro MG, Cowen R, Williamson IK, et al. Current and fu-ture strategies for the treatment of malignant brain tumors[J]. Pharmacol Ther, 2003, 98(1): 71-108.
  • 9Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosispathways in cancer therapy [J]. CA Cancer J Clin, 2005, 55(3): 178-194.
  • 10Gur G, Rubin C, Katz M, et al. LRIG1 restricts growth factorsignaling by enhancing receptor ubiquitylation and degra-dation [J]. EMBO J, 2004, 23(16): 3270-3281.

二级参考文献13

  • 1步星耀,胡明伟,张永福,李太平,梁庆华,王勇,薛绛宇.颅底脑膜瘤骨增生与骨侵袭的关系及临床意义[J].实用诊断与治疗杂志,2004,18(5):365-366. 被引量:4
  • 2步星耀,尹志华,冯少旭,张云龙,张永福.脑膜瘤硬脑膜侵袭的临床研究[J].实用诊断与治疗杂志,2005,19(1):10-11. 被引量:9
  • 3郭东生,韩林,舒凯,陈坚,雷霆.Down-regulation of Leucine-rich Repeats and Immunoglobulin-like Domain Proteins (LRIG1-3) in HP75 Pituitary Adenoma Cell Line[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2007,27(1):91-94. 被引量:11
  • 4Yamasaki F,Yoshioka H,Hama S,et al.Recurrence of meningiomas[J].Cancer,2000,89(5):1102-1110.
  • 5Kamitani H,Masuzawa H,Kanazawa I,et al.Recurrence of convexity meningioaas:tumor cells in the arachnoid membrane[J].Surg Neurol,2001,56(4):228-235.
  • 6DiMeco F,Li KW,Casali C,et al.Meningiomas invading the superior sagittal sinus:surgical experience in 108 cases[J].Neurosurgery,2004,55(6):1263-1272.
  • 7Fritz J,Roser F,Tatagiba M,et al.The basement membrane at the tumour-brain interface of brain-invasive grade I meningiomas[J].Neuropathol Appl Neurobiol,2005,31(3):339-342.
  • 8Perry A,Scheithauer BW,Stafford SL,et al."Malignancy"in meningiomas:a clinicopathologic study of 116 patients,with grading implications[J].Cancer,1999,85(9):2046-2056.
  • 9Guo D,Nilsson J,Haapasalo H,et al.Perinuclear leucinerich repeats and immunoglobulin-like domain proteins(LRIG1-3) as prognostic indicators in astrocytic tumors[J].Acta Neuropathol (Berl),2006,111(3):238-246.
  • 10Shattuck DL,Miller JK,Laederich M,et al.LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy[J].Mol Cell Biol,2007,27 (5):1934-1946.

共引文献8

同被引文献28

  • 1叶章群,严泽军,杨为民,郭东升.LRIG1基因对膀胱癌细胞侵袭力的影响[J].中华外科杂志,2007,45(4):258-261. 被引量:13
  • 2曾令成,欧一博,雷霆,郭东生.LRIG1在脑膜瘤中的表达及与其生物学行为的关系[J].中国临床神经外科杂志,2007,12(10):601-604. 被引量:7
  • 3Eisenstat DD,Gibson SB. RIGging functional outcomes in glioma cells:new insights into LRIG proteins in malignant gliomas[J]. Cancer Biol Ther,2009,8(11) :1024- 1026.
  • 4Nilsson J, Starefeidt A, Henriksson R, et al. LRIG1 pro- tein in human cells and tissues[J]. Cell Tissue Res,2003, 312(1):65-71.
  • 5Tanemura A,Nagasawa T,Inui S, et al. LRJG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin:immunohistochemical analysis for 38 cases[J]. Dermatal Surg,2005,31(4) :423-430.
  • 6Miller JK, Shattuck DL, Ingalla EQ, et al. Suppression of the negative regulator LRIG1 contributes to ErbB2 over- expression in breast cancer[J]. Cancer Res, 2008,68(20) : 8286-8294.
  • 7Wu X, Hedman H,Bergqvist M, et al. Expression of EG- FR and LRIG proteins in oesophageal carcinoma with em- phasis on patient survival and cellular chemosensitivity [J]. Acta Oncol,2012,51(1) :69-76.
  • 8Krig SR,Frietze S,Simion C,et al. Lrigl is an estrogen- regulated growth suppressor and correlates with longer relapse-free survival in ERa-positive breast cancer[J]. Mol Cancer Res,2011,9(10) :1406-1417.
  • 9Lingdstrom AK, Ekman K, Stendahl U, et al. LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis,other tumour markers, sex steroid hormones, and smoking[J]. Int J Gynecol Cancer, 2008,18(2) : 312- 317.
  • 10Goldoni S, Iozzo RA, Kay P, et al. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity[J]. Oncogene,2007,26(3) :368-381.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部